Women new to HT had no increased risk of breast cancer

	Tweet

In the 2006 subgroup analysis of WHI participants in the estrogen–progestin arm, investigators focused on HT use before enrollment in the trial. Recall that in this part of the WHI, 16,608 women with an intact uterus were randomized to conjugated equine estrogen plus medroxyprogesterone acetate or placebo. Use of the study medication was stopped after a mean follow-up of 5.6 years (mean exposure to HT: 4.4 years).

Overall, the risk of invasive breast cancer was slightly higher with combination HT than placebo (hazard ratio [HR] 1.24; 95% confidence interval [CI] 1.01–1.54).

In the 2006 report from the 2002 WHI study of estrogen–progestin HT versus placebo, investigators compared the risk of being diagnosed with breast cancer in 12,297 women who had not used HT prior to study enrollment with the risk in 4,311 participants who had previously used HT. Of the previous users, 42% reported less than 2 years of use prior to WHI enrollment, and 36% reported more than 4 years of HT prior to WHI enrollment.

The findings: Among WHI participants who had never before used HT, the use of estrogen–progestin HT in the study was not associated with an elevated risk of being diagnosed with breast cancer (HR 1.02; 95% CI 0.77–1.36). However, among previous HT users, the additional use of HT in the WHI study was associated with a risk nearly double that of placebo users (HR 1.96, 95% CI 1.17–3.27).

The reassuring results of this WHI subgroup analysis received little media attention in the United States, probably because the report appeared in a journal that has low readership in this country. WHI and other findings allow us to reassure women who have undergone hysterectomy that use of unopposed estrogen has little, if any, impact on breast cancer risk in menopausal women. This new WHI subgroup analysis, along with a recent review of European and North American data, allows ObGyns to counsel women with an intact uterus that up to 5 years of combination estrogen–progestin hormone therapy also has little, if any, impact on breast cancer risk.

RELATED STORIES:
Mechanism found connecting metastatic breast cancer and arthritis   Newer breast cancer drug seen safer than tamoxifen   ‘Pink ribbon dollars’ help fill financial gaps for breast cancer programs   Researchers discover new way to ‘rescue’ treatment sensitivity of breast cancer cells   Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women   COX-2 blockers may curb breast cancer risk   Risk of breast cancer recurrence may depend on treating surgeon   Alcohol may influence breast cancer recurrence   Breastfeeding, other factors may affect risk of breast cancer type   “Pre-vivors” Beat Cancer to the Punch   New Drug Cocktail Extends Lives of Patients with Advanced Breast Cancer   Vigorous exercise protects against breast cancer   The most aggressive forms of breast cancer elude the cellular control mechanisms in order to expand   Screening May Eventually Reduce Additional Breast Surgery   Plant-Based Diets May Improve Breast Cancer Survival   Breast Cancer Survivors May Face Second Cancers if they Smoke   Breast cancer incidence in Spain drops in early 2000s after decades of increasing rates   Clues to Pregnancy-Associated Breast Cancer Found   Breast Ducts: A New Site for Cancer Treatment?   Breast Cancer: What is an “early Stage” Breast Cancer   Even a little drinking may raise breast cancer risk: study   Tumor-free breast tissue can have precancerous changes

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]